Alternatively, our results implicate that combination administration of specific RAD51 inhibitors and RAD51-targeted chemodrugs could help reduce the occurrence of acquired resistance, thus providing an attractive strategy for the treatments of NSCLC patients. This evidence concerns the gene RAD51 and non-small cell lung carcinoma.